Restricted accessResearch articleFirst published online 2010-01
Localization of Candidate Genes in a Region of High Frequency of Microvariant Alleles for Prostate Cancer Susceptibility: The Chromosome Region Yp11.2 Genetic Variation
The Y chromosome has been suggested to play a role in prostate cancer (PCa) because the loss of this chromosome is the most common aberration in PCa. Study of short tandem repeats (STRs) could provide a means to rapidly scan genomes at known or unknown predisposing loci for some diseases. DNA samples from 281 patients with PCa at the Portuguese Institute of Oncology, Porto, Portugal, and a population control of 175 healthy controls were analyzed for region Yp11.2 using AmpFℓSTR® Y-Filer™ kit (Applied Biosystems). The results demonstrated that microvariant alleles of DYS458 are overrepresented (p = 0.026). We found that allele 12 of DYS393 and allele 19 of DYS458 could have a protective effect (p = 0.0051; odds ratio [OR] = 0.48; 95% confidence interval [95% CI] 0.27–0.38; and p = 0.0272; OR = 0.47; 95% CI 0.22–0.98). On the other hand, patients carrying allele 13 of DYS393 presented an increased risk to PCa (p = 0.015; OR = 1.97; 95% CI 1.26–3.07). These results are in concordance with the involvement of Y chromosome in PCa development. STR allele studies may add further information from the definition of a genetic profile of PCa resistance or susceptibility. As TSPY is located at region Yp11.2, this gene could play an essential role in PCa development.
Get full access to this article
View all access options for this article.
References
1.
AlersJ.C., RochatJ., KrijtenburgP.J., HopW.C.J., KranseR., RosenbergC., TankeH.J., SchoederF.H., DekkenH.2000. Identification of genetic markers for prostatic cancer progression. Lab Investig, 80:931–942.
2.
AlvesC., GomesV., PrataM.J., AmorimA., GusmãoL.2007. Population data for Y-chromosome haplotypes defined by 17 STRs (AmpFℓSTR® Y-Filer™) in Portugal. Forensic Sci Int, 171:250–255.
3.
BentoA.M., LopesV., SerraA., Afonso CostaH., AndradeL., BalsaF., AnjosM.J., CarvalhoM., OliveiraC., BatistaL., GameroJ.J., VieiraD.N., Corte-realF.2008. Population data for Y-chromosome haplotypes defined by 17 STRs (AmpFℓSTR® Y-Filer™) in Central Portugal. Forensic Sci Int Genet Suppl Ser, 1:179–180.
4.
ButlerJ.M.2005. Forensic DNA Typing, 2nd. Elsevier Academic Press: London.
5.
ChanM.J., StampferM.J., GiovannucciE.L.1998. What causes prostate cancer? A brief summary of the epidemiology. Semin Cancer Biol, 8:263–273.
6.
DasariV.K., GoharderakhshanR.Z., PerincheryG., LiL.C., TanakaY., AlonzoJ., DahikaR.2001. Expression analysis of Y chromosome genes in human prostate cancer. J Urol, 165:1335–1341.
7.
EkmanP.1993. Genetic and environmental factors in prostate cancer genesis: identifying high-risk cohorts. Eur Urol, 35:362–369.
8.
ErbersdoblerA., BardenhagenP., HenkeR.P.1999. Numerical Chromosomal anomalies in latent adenocarcinomas of the prostate. Prostate, 38:92–99.
9.
EwisA.A., LeeJ., NarodaT., SasaharaK., SanoT., KagawaS., IwamotoT., NakahoriY.2002. Linkage between prostate cancer incidence of the human Y-linked tetranucleotide polymorphism DYS19. J Med Investig, 49:56–60.
10.
FerriG., RobinoC., AlùM., LuiselliD., TofanelliS., CaciagliL., OnofriV., PelottiS., Di GaetanoC., CrobuF., BedushiG., CapelliC.2008. Molecular characterisation and population genetics of the DYS458 .2 allelic variant. Forensic Sci Int: Genet Suppl Ser, 1:203–205.
11.
FradetY., MeyerF., BairatiI., ShadmaniR., MooreL.1999. Dietary fat and prostate cancer progression and survival. Eur Urol, 35:388–391.
12.
GiovannucciE., RimmE.B., CoditzG.A., StampferM.J., AscherioA., ChuteC.C., WillettW.C.1993. A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst, 85:1571–1579.
13.
HansonE.K., BallantyneJ.2006. Comprehensive annotated STR physical map of the human Y chromosome: forensic implications. Leg Med, 8:110–120.
14.
HsingA.W., DevesaS.S.2001. Trends and patterns of prostate cancer: what do they suggest?Epidemiol Rev, 23:3–13.
15.
JordanJ.J., HanlonA.L., Al-SaleemT.I., GreenbergR.E., TricoliJ.V.2001. Loss of the short arm of Y chromosome in human prostate carcinoma. Cancer Genet Cytogenet, 124:122–126.
16.
KimptonC., GillP., D'AlojaE., AndersenJ.F., BarW., HolgerssonS., JacobsenS., JohnsonV., KloostermanA.D., LareuM.V., NellemannL., PfitzingerK., PhillipsC.P., RandS., SchmitterH., SchneiderH., SternersenM., VideM.C.1995. Report on the second EDNAP collaborative STR exercise. Forensic Sci Int, 71:137–152.
17.
KonigJ.J., TeubelW., RomijnJ.C., SchroederF.H., HagemeijerA.1996. Gain and Loss of Chromosomes 1, 7, 8, 10, 18 and Y in 46 Prostate Cancers. Hum Pathol, 27:720–727.
18.
LauY.C., ZhangJ.2000. Expression analysis of thirty one Y chromosome genes in human prostate cancer. Mol Carcinog, 27:308–321.
19.
LeviF., La VecchiaL., BoyleP.2000. The rise and fall of prostate cancer. Eur J Cancer Prev, 9:381–385.
20.
LewinB.Cell cycle and growth regulation. Genes VII. New York: Oxford University Press, 2000; 835–840.
21.
MedeirosR., MoraisA., VasconcelosA., CostaS., PintoD., OliveiraJ., LopesC.2002. The role of vitamin D receptor gene polymorphisms in the susceptibility to prostate cancer of a southern European population. J Hum Genet, 47:413–418.
22.
MedeirosR., VasconcelosA., CostaS., PintoD., FerreiraP., LoboF., MoraisA., OliveiraJ., LopesC.2004. Metabolic susceptibility genes and prostate cancer risk in a southern European population: the role of glutathione S-transferases GSTM1, GSTM3, and GSTT1 genetic polymorphisms. Prostate, 58:414–420.
23.
MedeirosR., VasconcelosA., CostaS., PintoD., MoraisA., OliveiraJ., LopesC.2003. Steroid hormone genotypes ARStuI and ER325 are linked to the progression of human prostate cancer. Cancer Genet Cytogenet, 141:91–96.
24.
MullenbachR., LagodaP.J., WelterC.1989. An efficient salt-chloroform extraction of DNA from blood and tissues. Trends Genet, 5:391.
25.
OramS.W., LiuX.X., LeeT.L., ChanW.Y., LauY.F.C.2006. TSPY potentiates cell proliferation and tumorigenesis by promoting cell cycle progression in HeLa and NIH3T3 cells. BMC Cancer, 6:154–168.
26.
ParacchiniS., PearceC.L., KolonelL.N., AltshulerD., HendersonB.E., Tyler-SmithC.2003. A Y chromosomal influence on prostate cancer risk: the multi-ethnic cohort study. J Med Genet, 40:815–819.
27.
ParkinM.1998. The global burden of cancer. Semin Cancer Biol, 8:60–67.
28.
PerincheryG., SasakiM., AnganA., KumarV., CarrollP., DahiyaR.2000. Deletion of Y-chromosome specific genes in human prostate cancer. J Urol, 163:1339–1342.
29.
PontesM.L., CainéL., AbrantesD., LimaG., PinheiroM.F.2007. Allele frequencies and population data for 17 Y-STR loci (AmpFℓSTR® Y-Filer™) in a Northern Portuguese population sample. Forensic Sci Int, 170:62–67.
30.
PorkkaK.P., VisakorpiT.2004. Molecular mechanisms of prostate cancer. Eur Urol, 45:683–691.
31.
RileyD.E., KriegerJ.N.2005. Short tandem repeat (STR) replacements in UTRs and introns suggest an important role for certain STRs in gene expression and disease. Gene, 344:203–211.
32.
RubinM.A., De MarzoA.M.2004. Molecular genetics of human prostate cancer. Mod Pathol, 17:380–388.
33.
SchaidD.J.2004. The complex genetic epidemiology of prostate cancer. Hum Mol Genet, 13:R103–R121.
SuzukiA., MarunoA., TahiraT., HayashiK.2001. Polar alteration of short tandem repeats (STRs) in mammalian cells. Mutat Res, 474:159–168.
37.
VijayakumarS., HallD.C., RevelesX.T., TroyerD.A., ThompsonI.M., GarciaD., XiangR.H., LeachR.J., Johnson-PaisT.L., NaylorS.L.2006. Detection of recurrent copy number loss at Yp11.2 involving TSPY gene cluster in prostate cancer using array-based comparative genomic hybridization. Cancer Res, 66:4055–4064.
